DNA Methylome Analysis In Blood Using The MethDet Technology: A Universal Media For Clinical Biomarkers | 8933
Journal of Molecular Biomarkers & Diagnosis
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
arly detection and differential diagnosis of a disease is a significant challenge. Asymptomatic disease present in an unknown
location in the body has to be identified precisely, inexpensively, and quickly. Only a few types of biomarkers can accomplish
this task, including epigenetic biomarkers based on Methylation of cell-free circulating DNA in blood.
In this presentation an overview of a novel technology for genome-wide detection of DNA methylation in ultra-small
samples, MethDet, will be presented alongside with results of the proof-of-principle platform for identification of abnormal DNA
methylation patterns in each sample. This platform allows identification of advanced adenoma of the colon, ductal carcinoma
, and stage I/II colon cancer. The possibility of differential diagnosis by blood analysis has been established by comparison of
patterns between benign lesions of the breast vs. ductal carcinoma, and benign ovarian disease vs. adenocarcinoma of the ovary.
Application of DNA methylome-wide analysis to differential diagnosis of cancer, psychiatric, and neurological diseases will be
discussed. Drug-specific changes in DNA methylation patterns detected in cell-free circulating DNA from blood of drug-exposed
patients will be demonstrated
Victor V. Levenson received his M.D. from the 2
Moscow State Medical Institute in Moscow, USSR and his Ph.D. in Cellular and Molecular Biology
from the Institute of Molecular Biology in Moscow, USSR, where he worked as a Junior Scientist, then Scientist, and Group Leader. After coming to
the US he was on faculty at Univercity of Illinois at Chicago, Nothwestern University and Rush University Medical Center where he developed the
proprietary MethDet technology. In 2010 he has co-founded US Biomarkers, Inc where he serves as President and CEO. He left academia in 2012
to concentrate on commercialization of biomarkers developed by the MethDet approach
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals